Ardelyx (ARDX) Free Cash Flow (2013 - 2026)
Ardelyx (ARDX) reported Free Cash Flow of -$32.3 million for Q1 2026, up 16.7% on a YoY basis from -$27.7 million in Q1 2025, and down 256.9% quarter-over-quarter from $20.6 million in Q4 2025.
Ardelyx (ARDX) Free Cash Flow (2013 - 2026) Analysis & Trends
Ardelyx has reported Free Cash Flow for 14 years, with the latest figure at -$32.3 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 16.7% year-over-year to -$32.3 million; the trailing twelve-month figure through Mar 2026 stood at -$37.5 million (up 23.05% YoY), and the FY2025 full-year result was -$44.0 million, up 4.03% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$32.3 million, down from $20.6 million in the prior quarter.
- The five-year high for Free Cash Flow was $20.6 million in Q4 2025, with the low at -$44.8 million in Q1 2023.
- Historically, Free Cash Flow has averaged -$16.6 million across 5 years, with a median of -$21.7 million in 2023.
- Annual changes were most pronounced in 2023 — Free Cash Flow slumped 161.57% — and 2024, when it jumped 205.2%.
- Ardelyx's Free Cash Flow stood at $14.2 million in 2022, then tumbled by 161.57% to -$8.8 million in 2023, then jumped by 205.2% to $9.2 million in 2024, then soared by 123.39% to $20.6 million in 2025, then sank by 256.9% to -$32.3 million in 2026.
- The last three Free Cash Flow figures came in at -$32.3 million (Q1 2026), $20.6 million (Q4 2025), and $209000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Ardelyx | 1.49 Bn | 1.25 Bn | 89.66 Mn | -32.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.31 Mn |
| Mar 31, 2026 | -32.31 Mn |
| Dec 31, 2025 | 20.59 Mn |
| Dec 31, 2025 | 20.59 Mn |
| Sep 30, 2025 | 209,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Jun 30, 2025 | -25.99 Mn |
| Jun 30, 2025 | -25.99 Mn |
| Mar 31, 2025 | -38.78 Mn |
| Mar 31, 2025 | -38.78 Mn |
| Dec 31, 2024 | 9.22 Mn |
| Dec 31, 2024 | 9.22 Mn |
| Sep 30, 2024 | 364,000.00 |
| Sep 30, 2024 | 364,000.00 |
| Jun 30, 2024 | -19.53 Mn |
| Jun 30, 2024 | -19.53 Mn |
| Mar 31, 2024 | -35.87 Mn |
| Mar 31, 2024 | -35.87 Mn |
| Dec 31, 2023 | -8.76 Mn |
| Dec 31, 2023 | -8.76 Mn |